The structure of IDS described here provides a much-needed snapshot of the enzyme defective in Hunter syndrome, delivering a detailed atomic framework for the rationalization and further understanding of disease-causing mutations, and supplying ‘blueprints' for the future development of new PCT agents or less immunogenic protein for ERT. The gene discussed is ELF3; the disease is mucopolysaccharidosis type 2.